



ORIGINAL ARTICLE

Prognostic model of survival outcomes in non-small cell lung cancer patients initiated on afatinib: pooled analysis of clinical trial data

Ashley M. Hopkins¹, Adel Shahnam², Sasha Zhang¹, Chris S. Karapetis¹, Andrew Rowland¹, Michael J. Sorich¹

¹Flinders Centre for Innovation in Cancer, Department of Clinical Pharmacology, College of Medicine and Public Health, Flinders University, Adelaide 5042, Australia; ²The Canberra Hospital, Garran 2605, Australia

ABSTRACT

Objective: Several predictors of survival have been identified in EGFR-positive non-small cell lung cancer (NSCLC) patients treated with first generation EGFR inhibitors. Prognostic models of survival outcomes with afatinib have not been evaluated.

Methods: A prognostic tool for overall survival (OS)/ progression free survival (PFS) based on pre-treatment clinicopathological factors was developed for EGFR-positive advanced NSCLC patients treated with first-line afatinib using penalised regression of individual-participant data from LUX-Lung 3 and 6 ($n = 468$). Favourable, intermediate and poor risk groups were identified and externally validated using LUX-Lung 1 ($n = 390$) and LUX-Lung 2 ($n = 129$) trials that initiated afatinib following previous chemotherapy or EGFR inhibitor treatment.

Results: Discriminative performance was good in the development and validation cohorts. For patients treated with first-line afatinib, the median OS for the favourable, intermediate and poor risk groups were > 47.7 , 29.3 and 16.4 months, respectively, and the median PFS were 17.3, 13.2 and 8.3 months, respectively. The improvement in median OS with afatinib use compared to chemotherapy was > 12.4 months for the favourable risk group, whereas no OS benefit was apparent for the poor risk group. The improvement in median PFS with afatinib use compared to chemotherapy was 10.2 months for the favourable risk group and 3.2 months for the poor risk group.

Conclusions: A prognostic tool was developed and validated to identify favourable, intermediate and poor risk groups for OS/PFS in EGFR-positive advanced NSCLC patients treated with afatinib. The prognostic groups can inform the likely absolute OS/PFS benefit expected from afatinib compared to chemotherapy in first-line treatment.

KEYWORDS

Afatinib; non-small cell lung cancer; prognostic model

Introduction

Validated clinical prediction tools that take into account the characteristics and circumstances of an individual patient to provide predictions of overall survival (OS) and progression free survival (PFS) can help inform the treatment expectations of patients and clinicians¹. Additionally, risk prediction tools may be particularly useful in identifying subgroups of patients that have more or less absolute benefit from treatment (i.e. heterogeneity of treatment effect)^{2,3}.

Epidermal growth factor receptor (EGFR) inhibitors are an effective first-line and above treatment option for advanced

NSCLC which harbors an activating EGFR mutation⁴. Afatinib is a second generation irreversible tyrosine kinase inhibitor which inhibits the signalling of ERBB receptor family members, including EGFR, HER2, ERBB3, and ERBB4. Afatinib has demonstrated improved PFS outcomes compared to gefitinib in EGFR-mutated NSCLC, but appears associated with an increased incidence of toxicity, although the rates of discontinuation are similar between agents⁵.

Several studies have investigated pre-treatment prognostic markers of OS and PFS for NSCLC patients who are initiated on gefitinib and erlotinib⁶⁻²⁰. The largest prior study assessed 398 NSCLC patients treated with erlotinib as a 2nd, 3rd or 4th line treatment⁸. The study developed an OS prognostic tool suitable for providing realistic treatment expectations, as well as identifying a small group of high risk patients that did not appear to obtain a survival benefit from erlotinib over placebo (i.e. demonstrated heterogeneity of treatment effect)⁸. The Florescu et al.⁸ prognostic tool was later

Correspondence to: Ashley M. Hopkins

E-mail: ashley.hopkins@flinders.edu.au

Received November 22, 2018; accepted February 26, 2019.

Available at www.cancerbiomed.org

Copyright © 2019 by Cancer Biology & Medicine

externally validated¹². However since this time, EGFR inhibitors have become a first-line treatment option, use of EGFR inhibitors has become restricted to patients with an activating EGFR mutation, and additional EGFR inhibitors have become available for advanced NSCLC. Thus the Florescu et al.⁸ prognostic tool has become outdated for contemporary practice. This study aimed to identify the pre-treatment prognostic markers of OS and PFS in EGFR-positive advanced NSCLC patients treated with first-line afatinib, to develop and validate a prognostic tool for OS and PFS in this population, and to evaluate whether the tool identifies heterogeneity of treatment benefit with use of afatinib.

Materials and methods

Data

Individual-participant data (IPD) from 4 clinical trials sponsored by Boehringer Ingelheim [LUX-Lung 1 (NCT00656136; trial no. 1200.23)²¹, LUX-Lung 2 (NCT00525148; 1200.22)^{22,23}, LUX-Lung 3 (NCT00949650; 1200.32)^{23,24}, and LUX-Lung 6 (NCT01121393; 1200.34)]²³⁻²⁵ were accessed via clinicalstudydatarequest.com. Secondary analysis of anonymised participant-level trial data was approved by Southern Adelaide Clinical Human Research Ethics Committee.

Development data for the prognostic tool consisted of EGFR-positive advanced NSCLC patients treated with first-line afatinib, with available OS and PFS data (LUX-Lung 3 and 6; $n = 468$). Data from patients from LUX-Lung 1 ($n = 390$) and LUX-Lung 2 ($n = 129$) were used as validation datasets. LUX-Lung 1 included patients who initiated afatinib (50 mg daily) following one or two lines of failed chemotherapy (including adjuvant chemotherapy), and had disease progression after at least 12 weeks of previous treatment with erlotinib, gefitinib or both²¹. LUX-Lung 2 included patients who initiated afatinib (40 mg or 50 mg daily) following no more than one previous chemotherapy regimen for advanced disease^{22,23}. Data from patients treated with first-line chemotherapy [pemetrexed-cisplatin (LUX-Lung 3) or gemcitabine-cisplatin (LUX-Lung 6)] were also available from LUX-Lung 3 and 6.

OS time was defined from the date of the first dose of afatinib (randomization) to the date of the last follow-up or death. PFS time was defined from the date of the first dose of afatinib (randomization) to the date of disease progression or death, whichever occurs first. Disease progression was

assessed by the investigators according to the Response Evaluation Criteria in Solid Tumours (RECIST): version 1.0 for LUX-Lung 1 and 2, and version 1.1 for LUX-Lung 3 and 6.

Pre-treatment continuous covariate data included age, time since diagnosis, body mass index (BMI), sum of longest tumor diameters (SLD), lactate dehydrogenase (LDH), alkaline phosphatase (ALP), total protein, platelets, haemoglobin, white blood cells, neutrophil to lymphocyte ratio (NLR), and lymphocyte to monocyte ratio (LMR). Pre-treatment categorical covariate data included sex, race, smoking history, Eastern Cooperative Oncology Group performance status (ECOG PS), previous treatment with chemotherapy or an EGFR inhibitor, and organs with metastasises (from liver, brain, bone, pleural effusion). For the laboratory defined data, clinically relevant high [i.e. above the upper limit of normal ($>ULN$)] and low [i.e. below the lower limit of normal ($<LLN$)] cut-offs were available, as defined by the reference range of the testing laboratory. LUX-Lung 1 was an enriched EGFR mutation positive cohort (i.e. 70% of study patients predicted to be EGFR mutation positive) and the specific mutation type of each study patient was unknown. For the remaining studies EGFR mutation type was provided.

Missing data was imputed using nonlinear additive imputation, which imputes missing values with the expected value based upon a maximized correlation of the variable with the best linear combination of the other variables.

Data analysis was conducted using R version 3.3.0, and the package *glmnet* was used to penalise the regression analyses.

Univariate analysis

Univariate Cox proportional hazard analysis was used to assess the crude association between common clinicopathologic factors and OS/PFS for patient treated with afatinib within a pooled analysis of LUX-Lung 3 and 6. The associations were reported as hazard ratios (HR) with 95% confidence intervals (95% CI), and P -values (likelihood ratio test). Right skewed continuous data were log transformed. Visual checks were used to assess potential non-linear effects of continuous variables, and the proportionality assumption. Where non-linear effects of continuous variables were identified, categorisation was tested, with model fit assessed through the use of the Akaike information criterion (AIC). The univariate Cox proportional hazard models were stratified by study. Interactions between study and the assessed univariates were investigated.

Development of a prognostic tool

A prognostic tool was developed using multivariable Cox proportional hazards regression analysis. The analysis was regularized using the least absolute shrinkage and selection operator (LASSO), a method that optimally selects the most useful predictors^{26,27}. The regularization penalty (λ) was chosen to be within 1 standard error of the minimum mean error based on a 20-fold cross validation.

Separate models were initially developed for prediction of PFS and OS. Modelling was initially conducted using the data transformations established in the univariate analysis, including the SLD variable. Subsequently, a sequence of simplifications were applied to develop a prognostic tool that may be more easily used in clinical practice. Continuous variables were dichotomised based upon the reference ranges for the testing laboratories and prior evidence of prognostic associations. While the SLD is an important prognostic variable, it is often not available in routine clinical practice and therefore was excluded from subsequent models. If the variables selected in the OS and PFS univariate and multivariable analyses were sufficiently similar, it was planned that the coefficients of the two multivariable models would be averaged and scaled from 0 to 5, to obtain a single prognostic score that could be used to predict both OS and PFS. Finally, the prognostic scores were grouped into the lower 25th (favourable risk), the middle 50th (intermediate risk) and upper 25th (poor risk) percentiles.

Discriminative performance was assessed in the development and validation datasets using the time-dependent area under the curve (tAUC) (calculated at 1 month intervals from 3 to 18 months). Kaplan-Meier analysis was used for plotting survival curves and estimating median survival.

Heterogeneity of treatment effect by prognostic group

In a pooled analysis of the intention to treated populations from LUX-Lung 3 and 6 ($n = 709$), methodology by Kent et al.² was used to evaluate the heterogeneity of treatment effect by risk on the absolute and proportional scale. Such analyses are important as substantial differences in the absolute benefit of treatment are common with varying risk². Kaplan-Meier analysis was used to plot and estimate the absolute difference in median OS and PFS for afatinib compared to chemotherapy for the identified prognostic groups. Cox proportional hazard analysis was used to assess the difference in OS and PFS for afatinib compared to chemotherapy across the range of prognostic scores on the proportional scale.

Results

Data

Table 1 provides a summary of the characteristics of the 468 patients that initiated first-line afatinib in LUX-Lung 3 and 6 (development data). **Supplementary Table S1** provides a summary of the characteristics of the 1,423 patients analysable in LUX-Lung 1, 2, 3 and 6.

Table 1 Summary of characteristics for patients treated with afatinib in LUX-Lung 3 and 6

Characteristics	Count/median (%/IQR)
Age group (years)	
27-65	314 (67.1%)
65-86	154 (32.9%)
Gender	
Female	299 (63.9%)
Male	169 (36.1%)
Race	
Asian	404 (86.3%)
White	61 (13%)
Other	3 (0.6%)
Smoking history	
Never smoked	332 (70.9%)
Ex or current smoker	136 (29.1%)
Time since diagnosis	
< 12 months	421 (90%)
> 12 months	47 (10%)
ECOG PS	
0	140 (29.9%)
1+	328 (70.1%)
EGFR mutation type	
DEL19	235 (50.3%)
L858R	180 (38.5%)
Other	41 (8.8%)
T790M	11 (2.4%)
WT	1 (0.2%)
Stage at screening	
IIIB	34 (7.3%)
IV	434 (92.7%)

Continued

Continued	
Characteristics	Count/median (%/IQR)
No. of organs with metastases	
0	106 (24.5%)
1	195 (45.1%)
2	105 (24.3%)
3	23 (5.3%)
4	3 (0.7%)
Missing	36 (7.7%)
BMI	23.23 (20.96-25.08)
SLD (mm)	53.5 (33.75-82)
ALP (U/L)	104 (78-186)
Missing	3 (0.6%)
LDH (U/L)	222.5 (173.75-338.5)
Missing	8 (1.7%)
Total protein (g/L)	70 (66-75)
Missing	5 (1.1%)
Platelets (x10 ⁹ /L)	270 (214-338)
Missing	1 (0.2%)
Haemoglobin (g/L)	130 (119-140.8)
Missing	1 (0.2%)
WBC (x10 ⁹ /L)	7.19 (5.8-8.8)
Missing	1 (0.2%)
NLR	2.95 (2.16-4.53)
Missing	1 (0.2%)
LMR	3.34 (2.24-4.69)
Missing	1 (0.2%)

<LLN, below the lower limit of normal; >ULN, above the upper limit of normal; ALP, alkaline phosphatase; BMI, body mass index; ECOG PS, Eastern Cooperative Oncology Group performance status; LDH, lactate dehydrogenase; LMR, lymphocyte to monocyte ratio; SLD, sum of longest tumor diameters; NLR, neutrophil to lymphocyte ratio; WBC, white blood cells; WT, wild type.

Univariate analysis

Univariate cox proportional hazard analysis of the development data (patients treated with afatinib in LUX-Lung 3 and 6) identified EGFR mutation type, sex, smoking history, time since diagnosis, line of therapy, ECOG PS, organs with metastases, BMI, log SLD, log LDH, platelets >ULN, haemoglobin < LLN, WBC >ULN, log NLR and log LMR as pre-treatment prognostic makers of OS and PFS in

patients treated with afatinib ($P < 0.05$, **Supplementary Table S2**). Additionally disease stage and log ALP were identified as significant predictors of OS only ($P < 0.05$, **Supplementary Table S2**). Based upon identified non-linear effects platelets, haemoglobin and WBC were dichotomised for the univariate analysis.

Prognostic tool

The multivariable Cox proportional hazards regression using LASSO variable selection, resulted in an OS model and a PFS model with tAUC's of 0.779 and 0.722, respectively, in the development data. Predictors selected for inclusion in both the OS and PFS models included EGFR mutation type, smoking history, time from diagnosis, organs with metastases, BMI, log SLD, log LDH, WBC >ULN, and log LMR as useful pre-treatment prognostic makers of OS and PFS in patients treated with afatinib (**Supplementary Table S3**). Additionally ECOG PS, stage at screening, and platelets >ULN were selected as useful predictors of OS, and sex was selected as a useful predictor of PFS.

In the first simplification of the above model, the SLD variable was excluded and continuous variables (BMI, ALP, LDH, total protein, NLR and LMR) were dichotomised prior to multivariable regression. The simplified OS and PFS models had a tAUC in the development data of 0.747 and 0.702, respectively. Predictors common to both the OS and PFS models included EGFR mutation type, smoking history, time from diagnosis, ECOG PS, organs with metastases, LDH >ULN, haemoglobin <LLN, WBC >ULN and LMR <3 (**Supplementary Table S4**). Additionally, stage at screening, and platelets >ULN were selected as predictors of OS, and sex was selected as a predictor of PFS (**Supplementary Table S4**).

Given the strong similarity of the simplified OS and PFS models, the two models were merged to develop a single combined prognostic score for both OS and PFS. The coefficients of the variables selected in the simplified OS and PFS models were averaged and scaled to an integer between 0 and 5 (**Supplementary Table S4**). **Table 2** presents the points (0 to 5) allocated for each predictor in order to calculate the prognostic score.

The prognostic tool was used to calculate a prognostic score for each patient treated with afatinib in LUX-Lung 3 and 6. The discrimination (tAUC) of the prognostic score in the development data was 0.750 for OS and 0.690 for PFS.

The prognostic scores were then grouped into favourable (lower 25th percentile: prognostic score of 7 or below), intermediate (middle 50th: 8 to 13) and poor risk groups (upper 25th: 14 or above). The discrimination (tAUC) of the

Table 2 Points allocated to each prognostic factor to calculate an overall prognostic score for OS and PFS.

	0	1	2	3	4	5
EGFR mutation	DEL19/L858R/ Other					T790M
Gender	Female	Male				
Smoking history	Never		Current or previous			
Time from diagnosis	>12 months				<12 months	
ECOG PS	0	1+				
Liver metastases	No			Yes		
Brain metastases	No			Yes		
Bone metastases	No			Yes		
Pleural effusion metastases	No			Yes		
LDH	Normal		>ULN			
Haemoglobin	Normal	<LLN				
WBC	Normal					>ULN
LMR below 3	No	Yes				

<LLN, below the lower limit of normal; >ULN, above the upper limit of normal; ECOG PS, Eastern Cooperative Oncology Group performance status; LDH, lactic dehydrogenase; LMR, lymphocyte to monocyte ratio; WBC, white blood cells

prognostic groups in the development data was 0.700 for OS and 0.661 for PFS. **Table 3** presents the median OS, median PFS, 36-month OS probability, and the 24-month PFS probability of patients treated with first-line afatinib in LUX-Lung 3 and 6 (development data). **Table 3** and **Supplementary Figure S1** demonstrate the variability in OS and PFS between prognostic groups.

External validation of prognostic groups

External prediction performance (discrimination) of the prognostic groups was evaluated in the afatinib treated patients from LUX-Lung 1 and LUX-Lung 2. The tAUC of the prognostic groups for the OS outcome was 0.697 and 0.747 for LUX-Lung 1 and LUX-Lung 2, respectively. The tAUC of the prognostic groups for the PFS outcome was 0.652 and 0.721 for LUX-Lung 1 and LUX-Lung 2, respectively.

Supplementary Figure S2, and **Supplementary Figure S3** visually present the prediction performance of the prognostic groups for OS and PFS in LUX-Lung 1 and LUX-Lung 2.

Heterogeneity of afatinib treatment benefit by prognostic group

Figure 1 visually presents the improvement in OS and PFS for afatinib compared to chemotherapy in the first-line setting (LUX-Lung 3 and 6) by prognostic group. The improvement in observed median OS with afatinib treatment (compared to chemotherapy) was > 12.4 months (> 47.7 vs. 35.3) for the favourable risk group, 6.2 months (28.5 vs. 22.3) for the intermediate risk group, and there was no apparent survival benefit (16.4 vs. 20.6) for the poor risk group. The improvement in observed median PFS with afatinib treatment (compared to chemotherapy) was 10.2 months

Table 3 Comparison of OS and PFS by prognostic group for patients treated with first-line afatinib in LUX-Lung 3 and 6

Prognostic group	Prognostic score	OS		PFS	
		Median [95% CI] T2E (month)	36-month OS probability (%)	Median [95% CI] T2E (month)	24-month PFS probability (%)
Favourable	7 or below	>47.7 [41.5->47.7]	61.2 [52.6-71.3]	17.3 [15-25.2]	40.2 [31.9-50.7]
Intermediate	8 to 13	29.3 [24.2-31.7]	35.6 [29.4-43.1]	13.2 [11-13.9]	18.5 [14-24.6]
Poor	14 or above	16.4 [14-19.6]	13.6 [8.3-22.4]	8.3 [6.7-10.8]	8.9 [5.1-15.6]

CI, confidence interval; OS, overall survival; PFS, progression free survival; T2E, time to event




Figure 1 Comparison of OS (A, C, E) and PFS (B, D, F) by prognostic group for afatinib versus chemotherapy (CTx) treated patients.

(17.3 vs. 7.1) for the favourable risk group, 7.6 months (13.2 vs. 5.6) for the intermediate risk group, and 3.2 months (8.3 vs. 5.1) for the poor risk group.

Cox proportional hazard analysis identified a significant interaction (relative difference) between treatment (afatinib versus chemotherapy) effect and prognostic score on OS ($P =$

0.006); no interaction between treatment (afatinib versus chemotherapy) effect and prognostic score on PFS was identified ($P = 0.150$). **Supplementary Figure S4** presents the relative difference in treatment (afatinib versus chemotherapy) effect on OS and PFS by prognostic group.

Discussion

A pre-treatment prognostic tool for OS and PFS in EGFR-positive advanced NSCLC patients treated with first-line afatinib was developed based on large and high-quality data. The prognostic tool was able to clearly distinguish favourable, intermediate and poor risk groups. External validation indicated that the prognostic groups maintained good discrimination even in patients using afatinib at later lines of therapy (i.e. following prior chemotherapy or gefitinib/erlotinib). Additionally, the median OS and PFS benefit of first-line afatinib over chemotherapy differed substantially between the favourable, intermediate and poor risk groups.

The present analysis of pre-treatment prognostic markers of OS and PFS in EGFR-positive advanced NSCLC patients treated with an EGFR inhibitor is to the best of the authors knowledge the largest study in this patient group conducted to date ($n = 987$). This study is also the largest to develop a pre-treatment prediction model applicable to the first-line use of an EGFR inhibitor for EGFR-positive advanced NSCLC. The largest prior study assessed 398 NSCLC patients treated with erlotinib as a 2nd, 3rd or 4th line treatment⁸. The clinical prediction model developed by Florescu et al⁸ included EGFR-FISH gene copy number as a predictor which is not relevant to contemporary use of EGFR inhibitors. It also included response to prior therapy and number of prior therapies as predictors, which are not applicable to first-line use of an EGFR inhibitor.

The predictors of OS and PFS identified were generally in concordance with previous literature investigating EGFR-positive advanced NSCLC patients treated with EGFR inhibitors⁶⁻²⁰. These included EGFR mutation type, sex, smoking history, BMI, time since diagnosis, line of therapy, ECOG PS, disease stage, organs with metastases, SLD, ALP, LDH, platelets, hemoglobin, WBC, NLR and LMR.

The prognostic tool developed in this study allows the simultaneous interpretation of both OS and PFS prognostic risk for individuals commencing first-line afatinib therapy for EGFR-positive advanced NSCLC. The median OS, median PFS, 3-year OS, and 24-month PFS estimates presented here are applicable only to this patient population. However, the validation datasets indicate that the prognostic

groups also perform well in individuals using afatinib (40 mg or 50 mg daily) in later lines, for example, following one or two lines of failed chemotherapy (including adjuvant chemotherapy) and failed erlotinib, gefitinib or both (LUX-Lung 1)²¹, or following no more than one previous chemotherapy regimen for advanced disease (LUX-Lung 2)^{22, 23}. Thus, although the absolute survival estimates are not applicable to individuals using afatinib in later lines, this indicates that the risk groups are still able to identify individuals at higher than average risk and lower than average risk. For example, the median OS (95% CI) for afatinib treated patients in the favourable, intermediate and poor risk groups from LUX-Lung 2 respectively were 66.2 (39.35-96.6), 24.4 (20.3-33.4), and 11.2 (6.4-18.9) months [**Supplementary Figure S3**; LUX-Lung 2 included patients who initiated afatinib (40 mg or 50 mg daily) following no more than one previous chemotherapy regimen for advanced disease^{22, 23}].

The prognostic tool was developed with a particular focus on facilitating clinical use and interpretability. This included limiting predictors to those that are routinely available in clinical practice (e.g. excluding SLD), selecting simple cut points for continuous variables, selecting the minimal number of predictors that maintain good prediction performance, developing a single risk score to predict both OS and PFS, and grouping the score into favourable, intermediate and poor prognostic groups. Each of these simplifications resulted in some reduction in prediction performance, and yet the final risk groups displayed good performance on external validation. The initial more complex prediction model is also reported here should optimal prediction performance be preferred over simplicity of use.

A notable finding is that the median OS and PFS benefit of afatinib versus chemotherapy differs substantially between prognostic groups. Prognostic tools are an important method of exploring heterogeneity of treatment effect³, and prognostic tools have demonstrated particular value in identifying subgroups with substantially different absolute treatment benefit². There are many good examples in general medicine although there are very few examples of its application in the setting of advanced cancer. Florescu et al.⁸ previously demonstrated that a higher prognostic score was associated with a loss of survival benefit when comparing erlotinib to placebo in 2nd, 3rd or 4th line patients. In this study, the favourable risk group was observed to have more than a 12.4 month median survival benefit for a patient treated with afatinib compared to chemotherapy. In contrast, no survival benefit for afatinib was observed in patients with

a poor risk. Regardless of prognostic group median PFS was superior in the afatinib treated patients compared to chemotherapy, but the size of the benefit was substantially higher for the favourable risk group (10.2 months) compared to the poor risk group (3.2 months). The disparity between the observed benefit of afatinib on survival and PFS in the poor risk group are likely influenced by the high proportion of cross over from chemotherapy to EGFR inhibitor therapy observed after study completion and the strong response to EGFR inhibitors in the salvage setting^{23-25,28}.

Clinical trials and randomised control trials are the backbone of evidence based medicine. However, their generalisability to the real-world population can be limited by the inclusion and exclusion criteria of the individual trials²⁹. In this study, IPD from 4 clinical trials was used for model development and validation. Validation on studies of afatinib use in subsequent lines of therapy demonstrated generalisability of risk groups across lines of therapy. Ideally the developed prognostic tool will be validated and recalibrated if necessary using a real-world population dataset. Additionally, it will be useful to evaluate whether the prognostic tool is applicable to all EGFR inhibitors, thus an important future direction will be the validation of the tool using data from individuals treated with erlotinib, gefitinib or osimertinib.

In conclusion, a prognostic tool for OS and PFS in EGFR-positive advanced NSCLC patients treated with afatinib was developed and validated using data from previously completed clinical trials. The selected variables were in concordance with the previous literature and are all routinely available in the clinic. Risk groups are associated with different degrees of OS and PFS benefit for afatinib compared to chemotherapy in the first-line setting. Thus, there is the potential for the developed prognostic tool to help inform treatment decisions and provide more realistic treatment expectations.

Acknowledgements

This work was supported by a grant from Cancer Council South Australia's Beat Cancer Project on behalf of its donors and the State Government through the Department of Health (Grant No. 1159924 and 1127220). A.M.H is a researcher funded by a Postdoctoral Fellowship from the National Breast Cancer Foundation, Australia (Grant No. PF-17-007).

Conflict of interest statement

No potential conflicts of interest are disclosed.

References

1. Adams ST, Leveson SH. Clinical prediction rules. *BMJ*. 2012; 344: d8312.
2. Kent DM, Nelson J, Dahabreh IJ, Rothwell PM, Altman DG, Hayward RA. Risk and treatment effect heterogeneity: re-analysis of individual participant data from 32 large clinical trials. *Int J Epidemiol*. 2016; 45: 2075-88.
3. Kent DM, Rothwell PM, Ioannidis JP, Altman DG, Hayward RA. Assessing and reporting heterogeneity in treatment effects in clinical trials: a proposal. *Trials*. 2010; 11: 85.
4. Chen G, Feng J, Zhou C, Wu YL, Liu XQ, Wang C, et al. Quality of life (QoL) analyses from OPTIMAL (CTONG-0802), a phase III, randomised, open-label study of first-line erlotinib versus chemotherapy in patients with advanced *EGFR* mutation-positive non-small-cell lung cancer (NSCLC). *Ann Oncol*. 2013; 24: 1615-22.
5. Park K, Tan EH, O'Byrne K, Zhang L, Boyer M, Mok T, et al. Afatinib versus gefitinib as first-line treatment of patients with *EGFR* mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial. *Lancet Oncol*. 2016; 17: 577-89.
6. Aydiner A, Yildiz I, Seyidova A. Clinical outcomes and prognostic factors associated with the response to erlotinib in non-small-cell lung cancer patients with unknown *EGFR* mutational status. *Asian Pac J Cancer Prev*. 2013; 14: 3255-61.
7. Faehling M, Eckert R, Kuom S, Kamp T, Stoiber KM, Schumann C. Benefit of erlotinib in patients with non-small-cell lung cancer is related to smoking status, gender, skin rash and radiological response but not to histology and treatment line. *Oncology*. 2010; 78: 249-58.
8. Florescu M, Hasan B, Seymour L, Ding K, Shepherd FA. A clinical prognostic index for patients treated with erlotinib in National Cancer Institute of Canada Clinical Trials Group study BR.21. *J Thorac Oncol*. 2008; 3: 590-8.
9. Krawczyk P, Kowalski DM, Krawczyk KW, Szczyrek M, Mlak R, Rolski A, et al. Predictive and prognostic factors in second- and third-line erlotinib treatment in NSCLC patients with known status of the *EGFR* gene. *Oncol Rep*. 2013; 30: 1463-72.
10. Kaneda H, Tamura K, Kurata T, Uejima H, Nakagawa K, Fukuoka M. Retrospective analysis of the predictive factors associated with the response and survival benefit of gefitinib in patients with advanced non-small-cell lung cancer. *Lung Cancer*. 2004; 46: 247-54.
11. Cha YK, Lee HY, Ahn MJ, Choi YL, Lee JH, Park K, et al. Survival outcome assessed according to tumor burden and progression patterns in patients with epidermal growth factor receptor mutant lung adenocarcinoma undergoing epidermal growth factor receptor tyrosine kinase inhibitor therapy. *Clin Lung Cancer*. 2015; 16: 228-36.
12. Wang FH, Zhang Y, Zhao HY, Chen LK, Shi YX, Zhang L. Validation of a clinical prognostic model in Chinese patients with metastatic and advanced pretreated non-small cell lung cancer

- treated with gefitinib. *Med Oncol*. 2011; 28: 331-5. (in Chinese)
13. Chen YM, Lai CH, Chang HC, Chao TY, Tseng CC, Fang WF, et al. The impact of clinical parameters on progression-free survival of non-small cell lung cancer patients harboring EGFR-mutations receiving first-line EGFR-tyrosine kinase inhibitors. *Lung Cancer*. 2016; 93: 47-54.
 14. Cioffi P, Marotta V, Fanizza C, Gigliani A, Natoli C, Petrelli F, et al. Effectiveness and response predictive factors of erlotinib in a non-small cell lung cancer unselected European population previously treated: a retrospective, observational, multicentric study. *J Oncol Pharm Pract*. 2013; 19: 246-53.
 15. Jiang T, Cheng RR, Zhang GW, Su CX, Zhao C, Li XF, et al. Characterization of liver metastasis and its effect on targeted therapy in EGFR-mutant NSCLC: a multicenter study. *Clin Lung Cancer*. 2017; 18: 631-9.
 16. Fukihara J, Watanabe N, Taniguchi H, Kondoh Y, Kimura T, Kataoka K, et al. Clinical predictors of response to EGFR tyrosine kinase inhibitors in patients with EGFR-mutant non-small cell lung cancer. *Oncology*. 2014; 86: 86-93.
 17. Lee JY, Lim SH, Kim M, Kim S, Jung HA, Chang WJ, et al. Is there any predictor for clinical outcome in EGFR mutant NSCLC patients treated with EGFR TKIs? *Cancer Chemother Pharmacol*. 2014; 73: 1063-70.
 18. Yao ZH, Liao WY, Ho CC, Chen KY, Shih JY, Chen JS, et al. Real-world data on prognostic factors for overall survival in EGFR mutation-positive advanced non-small cell lung cancer patients treated with first-line gefitinib. *Oncologist*. 2017; 22: 1075-83.
 19. Wu KL, Tsai MJ, Yang CJ, Chang WA, Hung JY, Yen CJ, et al. Liver metastasis predicts poorer prognosis in stage IV lung adenocarcinoma patients receiving first-line gefitinib. *Lung Cancer*. 2015; 88: 187-94.
 20. Park JH, Kim TM, Keam B, Jeon YK, Lee SH, Kim DW, et al. Tumor burden is predictive of survival in patients with non-small-cell lung cancer and with activating epidermal growth factor receptor mutations who receive gefitinib. *Clin Lung Cancer*. 2013; 14: 383-9.
 21. Miller VA, Hirsh V, Cadranal J, Chen YM, Park K, Kim SW, et al. Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial. *Lancet Oncol*. 2012; 13: 528-38.
 22. Yang JCH, Shih JY, Su WC, Hsia TC, Tsai CM, Ou SHI, et al. Afatinib for patients with lung adenocarcinoma and epidermal growth factor receptor mutations (LUX-Lung 2): a phase 2 trial. *Lancet Oncol*. 2012; 13: 539-48.
 23. Yang JCH, Sequist LV, Geater SL, Tsai CM, Mok TSK, Schuler M, et al. Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon *EGFR* mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6. *Lancet Oncol*. 2015; 16: 830-8.
 24. Yang JCH, Wu YL, Schuler M, Sebastian M, Popat S, Yamamoto N, et al. Afatinib versus cisplatin-based chemotherapy for *EGFR* mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials. *Lancet Oncol*. 2015; 16: 141-51.
 25. Wu YL, Zhou CC, Hu CP, Feng JF, Lu S, Huang YC, et al. Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring *EGFR* mutations (LUX-Lung 6): an open-label, randomised phase 3 trial. *Lancet Oncol*. 2014; 15: 213-22.
 26. Halabi S, Lin CY, Kelly WK, Fizazi KS, Moul JW, Kaplan EB, et al. Updated prognostic model for predicting overall survival in first-line chemotherapy for patients with metastatic castration-resistant prostate cancer. *J Clin Oncol*. 2014; 32: 671-7.
 27. Huang YQ, Liang CH, He L, Tian J, Liang CS, Chen X, et al. Development and validation of a radiomics nomogram for preoperative prediction of lymph node metastasis in colorectal cancer. *J Clin Oncol*. 2016; 34: 2157-64.
 28. Soria JC, Mok TS, Cappuzzo F, Jänne PA. *EGFR*-mutated oncogene-addicted non-small cell lung cancer: current trends and future prospects. *Cancer Treat Rev*. 2012; 38: 416-30.
 29. Kibbelaar RE, Oortgiesen BE, van der Wal-Oost AM, Boslooper K, Coebergh JW, Veeger NJGM, et al. Bridging the gap between the randomised clinical trial world and the real world by combination of population-based registry and electronic health record data: a case study in haemato-oncology. *Eur J Cancer*. 2017; 86: 178-85.
- Cite this article as:** Hopkins AM, Shahnam A, Zhang S, Karapetis CS, Rowland A, Sorich MJ. Prognostic model of survival outcomes in non-small cell lung cancer patients initiated on afatinib: pooled analysis of clinical trial data. *Cancer Biol Med*. 2019; 16: 341-9. doi: 10.20892/j.issn.2095-3941.2018.0474

Supplementary materials

Table S1 Summary of patient characteristics by study.

Characteristics	LUX-Lung 1 (BI_1200.23)	LUX-Lung 2 (BI_1200.22)	LUX-Lung 3 (BI_1200.32)	LUX-Lung 6 (BI_1200.34)
Total	585 (41.1%)	129 (9.1%)	345 (24.2%)	364 (25.6%)
Per-protocol population				
N	0 (0%)	0 (0%)	5 (1.4%)	12 (3.3%)
Y	585 (100%)	129 (100%)	340 (98.6%)	352 (96.7%)
Age group				
27-65	402 (68.7%)	73 (56.6%)	211 (61.2%)	278 (76.4%)
65-86	183 (31.3%)	56 (43.4%)	134 (38.8%)	86 (23.6%)
Sex				
F	348 (59.5%)	75 (58.1%)	224 (64.9%)	238 (65.4%)
M	237 (40.5%)	54 (41.9%)	121 (35.1%)	126 (34.6%)
Race				
Asian	383 (65.5%)	112 (86.8%)	249 (72.2%)	364 (100%)
Other	9 (1.5%)	17 (13.2%)	5 (1.4%)	0 (0%)
White	193 (33%)	0 (0%)	91 (26.4%)	0 (0%)
Smoking history				
Never smoked	366 (62.6%)	82 (63.6%)	236 (68.4%)	280 (76.9%)
Ex or current smoker	219 (37.4%)	47 (36.4%)	109 (31.6%)	84 (23.1%)
Time since diagnosis				
< 12 months	59 (10.1%)	105 (81.4%)	307 (89%)	336 (92.3%)
> 12 months	525 (89.9%)	24 (18.6%)	38 (11%)	28 (7.7%)
missing	1 (0.2%)	0 (0%)	0 (0%)	0 (0%)
Treatment				
Chemotherapy/placebo	195 (33.3%)	0 (0%)	115 (33.3%)	122 (33.5%)
Afatinib 40 mg	0 (0%)	30 (23.3%)	230 (66.7%)	242 (66.5%)
Afatinib 50 mg	390 (66.7%)	99 (76.7%)	0 (0%)	0 (0%)
Previous therapies used				
Chemotherapy	0 (0%)	71 (55%)	17 (4.9%)	21 (5.8%)
EGFR and chemotherapy	585 (100%)	0 (0%)	0 (0%)	0 (0%)
None	0 (0%)	58 (45%)	328 (95.1%)	343 (94.2%)
ECOG PS				
0	145 (24.8%)	83 (64.3%)	133 (38.6%)	89 (24.5%)
1+	440 (75.2%)	46 (35.7%)	212 (61.4%)	275 (75.5%)
EGFR mutation type				
DEL19	0 (0%)	52 (40.3%)	169 (49.1%)	186 (51.1%)

Continued

Continued

Characteristics	LUX-Lung 1 (BI_1200.23)	LUX-Lung 2 (BI_1200.22)	LUX-Lung 3 (BI_1200.32)	LUX-Lung 6 (BI_1200.34)
L858R	0 (0%)	54 (41.9%)	138 (40.1%)	138 (37.9%)
Other	0 (0%)	23 (17.8%)	25 (7.3%)	38 (10.4%)
T790M	0 (0%)	0 (0%)	12 (3.5%)	2 (0.5%)
WT	0 (0%)	0 (0%)	1 (0.3%)	0 (0%)
Missing	585 (100%)	0 (0%)	0 (0%)	0 (0%)
Stage at screening				
IIIB	21 (3.6%)	8 (6.2%)	37 (10.7%)	22 (6%)
IV	564 (96.4%)	121 (93.8%)	308 (89.3%)	342 (94%)
No. of organs with metastases				
0	117 (23.5%)	41 (31.8%)	83 (26.8%)	100 (28.7%)
1	179 (35.9%)	49 (38%)	132 (42.6%)	158 (45.4%)
2	121 (24.3%)	37 (28.7%)	69 (22.3%)	76 (21.8%)
3	72 (14.5%)	1 (0.8%)	23 (7.4%)	13 (3.7%)
4	9 (1.8%)	1 (0.8%)	3 (1%)	1 (0.3%)
Missing	87 (14.9%)	0 (0%)	35 (10.1%)	16 (4.4%)
BMI	23.53 [21.46-26.11]	24.05 [21.92-26.24]	23.45 [20.79-25.68]	22.99 [20.83-24.59]
Missing	12 (2.1%)	1 (0.8%)	0 (0%)	0 (0%)
SLD (mm)	60.45 [36-99.1]	67 [39-105]	55 [33-84]	50 [32-72.25]
Missing	1 (0.2%)	0 (0%)	0 (0%)	0 (0%)
ALP (U/L)	94 [72-127]	124 [78-178]	125 [84-229.25]	92 [74-120]
Missing	8 (1.4%)	0 (0%)	3 (0.9%)	1 (0.3%)
LDH (U/L)	259 [183-387]	222 [153-411]	248.5 [182.75-383]	207.5 [163.75-272.25]
Missing	20 (3.4%)	0 (0%)	5 (1.4%)	4 (1.1%)
Total protein (g/L)	73 [68-77]	72 [70-77]	71 [67-75]	70 [65.62-74.8]
Missing	25 (4.3%)	0 (0%)	3 (0.9%)	2 (0.5%)
Platelets (x10 ⁹ /L)	257 [207.5-325.5]	248 [201-298]	273 [225-350]	255.2 [203.5-318.5]
Missing	6 (1%)	0 (0%)	0 (0%)	1 (0.3%)
Haemoglobin (g/L)	126 [115-136]	127 [111-140]	130 [120-140]	129 [121-140]
Missing	5 (0.9%)	0 (0%)	0 (0%)	1 (0.3%)
WBC (x10 ⁹ /L)	6.91 [5.69-8.6]	6.9 [5.7-8.31]	7.2 [5.72-9.14]	7.19 [5.77-8.8]
Missing	5 (0.9%)	0 (0%)	0 (0%)	1 (0.3%)
NLR	3.16 [2.08-5]	3.05 [1.93-4.22]	3.17 [2.11-4.77]	2.8 [1.99-3.99]
Missing	5 (0.9%)	0 (0%)	0 (0%)	1 (0.3%)
LMR	2.75 [1.83-4.19]	3.63 [2.25-5.08]	3.29 [2.25-4.8]	3.59 [2.43-4.94]
Missing	5 (0.9%)	0 (0%)	0 (0%)	2 (0.5%)

<LLN, below the lower limit of normal; >ULN, above the upper limit of normal; ALP, alkaline phosphatase; BMI, body mass index; ECOG PS, Eastern Cooperative Oncology Group performance status; LDH, lactate dehydrogenase; LMR, lymphocyte to monocyte ratio; SLD, sum of longest tumour diameters; NLR, neutrophil to lymphocyte ratio; WBC, white blood cells, WT, wild type.

Table S2 Univariate cox proportional hazard analysis of potential predictors of OS and PFS for patients treated with first-line afatinib (Lux-Lung 3 and 6).

Variable	OS					PFS			
	<i>n</i>	Events	Median [95% CI] T2E (months)	HR [95% CI]	<i>p</i>	Events	Median [95% CI] T2E (months)	HR [95% CI]	<i>p</i>
Age					0.702				0.087
27-65	314	205	26.2 [22.1-29.8]			277	13.6 [11.1-13.8]		
65-86	154	93	26.1 [23.0-33.9]	0.95 [0.74-1.22]		121	11.3 [9.5-14.3]	0.83 [0.67-1.03]	
Sex					0.023				< 0.001
F	299	181	27.4 [24.2-32.9]			244	13.7 [12.4-16.4]		
M	169	117	22.4 [19.6-27.7]	1.31 [1.04-1.66]		154	11.0 [8.4-12.0]	1.48 [1.21-1.81]	
Race					0.514				0.875
Asian	404	260	26.1 [23.1-30.0]			349	13.6 [11.1-13.8]		
Other/white	64	38	26.6 [21.1-33.9]	1.13 [0.78-1.65]		49	9.8 [6.8-13.7]	1.03 [0.74-1.42]	
Smoking History					< 0.001				< 0.001
Never smoked	332	200	27.7 [24.8-31.7]			276	13.8 [13.6-15.7]		
Ex or current smoker	136	98	20.2 [17.5-26.2]	1.53 [1.19-1.95]		122	8.9 [6.9-11.1]	1.56 [1.26-1.94]	
Time since diagnosis					< 0.001				< 0.001
> 12 months	47	16	NA [34.3-NA]			32	19.4 [11.1-30.3]		
< 12 months	421	282	24.2 [22.1-27.2]	2.65 [1.60-4.39]		366	12.1 [10.9-13.7]	2.00 [1.39-2.88]	
Line of therapy					< 0.001				0.002
1st	442	289	24.8 [22.5-27.7]			381	12.5 [11.0-13.7]		
2+	26	9	42.2 [32.9-NA]	0.38 [0.20-0.74]		17	19.4 [10.8-32.4]	0.51 [0.31-0.83]	
ECOG PS					0.001				< 0.001
0	140	73	32.4 [27.2-NA]			108	13.7 [12.1-16.6]		
1+	328	225	23.2 [20.5-26.8]	1.55 [1.18-2.04]		290	11.3 [9.8-13.7]	1.48 [1.18-1.86]	
EGFR mutation type					< 0.001				< 0.001
DEL19	235	134	31.7 [28.1-35.3]			195	13.9 [13.7-16.5]		
L858R	180	124	22.1 [19.6-25.8]	1.55 [1.21-1.98]		156	11.1 [9.6-13.7]	1.29 [1.05-1.60]	
Other	41	30	17.3 [14.0-21.0]	2.01 [1.34-2.99]		35	6.9 [4.6-9.7]	1.82 [1.26-2.61]	

Continued

Continued

Variable	OS					PFS				
	<i>n</i>	Events	Median [95% CI] T2E (months)	HR [95% CI]	<i>p</i>	Events	Median [95% CI] T2E (months)	HR [95% CI]	<i>p</i>	
T790M	11	9	20.8 [7.5-24.9]	3.11 [1.56-6.22]		11	2.8 [1.3-9.5]	3.84 [2.06-7.17]		
Stage at screening					0.017				0.166	
IIIB	34	16	42.2 [26.6-NA]			28	16.5 [9.7-22.1]			
IV	434	282	24.8 [22.2-27.7]	1.76 [1.06-2.93]		370	12.7 [11.0-13.7]	1.30 [0.88-1.91]		
No. of organs with metastases				1.56 [1.37-1.78]	< 0.001			1.36 [1.21-1.52]	< 0.001	
BMI				0.96 [0.92-0.99]	0.009			0.95 [0.92-0.98]	< 0.001	
Log SLD (mm)				1.74 [1.43-2.12]	< 0.001			1.81 [1.53-2.14]	< 0.001	
Log ALP (U/L)				1.37 [1.15-1.63]	< 0.001			1.14 [0.98-1.34]	0.098	
Log LDH (U/L)				1.92 [1.53-2.43]	< 0.001			1.52 [1.24-1.87]	< 0.001	
Total protein (g/L)				0.99 [0.97-1.00]	0.101			0.99 [0.97-1.00]	0.135	
Platelets > ULN					0.001				0.012	
N	367	223	29.8 [25.4-32.1]			308	13.7 [11.1-13.9]			
Y	101	75	20.0 [16.0-23.6]	1.58 [1.21-2.06]		90	10.8 [7.0-13.7]	1.37 [1.08-1.74]		
Haemoglobin < LLN					< 0.001				< 0.001	
N	367	220	29.3 [25.8-33.0]			305	13.7 [12.3-13.9]			
Y	101	78	19.6 [16.6-22.1]	1.90 [1.46-2.49]		93	9.7 [6.9-11.0]	1.56 [1.23-1.99]		
WBC > ULN					< 0.001				< 0.001	
N	389	235	29.8 [26.1-32.1]			327	13.7 [12.7-14.4]			
Y	79	63	15.1 [11.8-18.2]	2.42 [1.82-3.21]		71	6.9 [5.3-10.8]	1.90 [1.47-2.47]		
Log NLR				1.73 [1.42-2.11]	< 0.001			1.47 [1.24-1.74]	< 0.001	
Log LMR				0.54 [0.43-0.66]	< 0.001			0.66 [0.55-0.79]	< 0.001	

<LLN, below the lower limit of normal; > ULN, above the upper limit of normal; ALP, alkaline phosphatase; BMI, body mass index; ECOG PS, Eastern Cooperative Oncology Group performance status; LDH, lactate dehydrogenase; LMR, lymphocyte to monocyte ratio; SLD, sum of longest tumour diameters; NLR, neutrophil to lymphocyte ratio; WBC, white blood cells.

Table S3 Model coefficients for the multivariable cox proportional hazards regression of the data transformations derived from the univariate analysis, including SLD, for the OS and PFS events in patients treated with afatinib in LUX-Lung 3 and 6.

Variable	Coefficients - OS model	Coefficients - PFS model
Age		
27-65	.	.
65-86	NA	NA
Sex		
F	.	.
M	NA	0.048
Race		
Asian	.	.
Other	NA	NA
Smoking history		
Never smoked	.	.
Ex or current smoker	0.056	0.162
Time since diagnosis		
> 12 months	.	.
< 12 months	0.118	0.061
Any previous treatment		
No	.	.
Yes	NA	NA
ECOG PS		
0	.	.
1+	0.038	NA
EGFR mutation type		
DEL19	.	.
L858R	0.020	NA
Other	NA	NA
T790M	NA	0.262
Stage at screening		
IIIB	.	.
IV	0.012	NA
No. of organs with metastases	0.177	0.112
BMI	-0.009	-0.018
Log SLD (mm)	0.167	0.355
Log ALP (U/L)	NA	NA
Log LDH (U/L)	0.155	0.100

Continued

Continued

Variable	Coefficients - OS model	Coefficients - PFS model
Total protein (g/L)	NA	NA
Platelets > ULN		
N	.	.
Y	0.009	NA
Haemoglobin < LLN		
N	.	.
Y	NA	NA
WBC > ULN		
N	.	.
Y	0.230	0.107
Log NLR	NA	NA
Log LMR	-0.177	-0.049

<LLN, below the lower limit of normal; > ULN, above the upper limit of normal; ALP, alkaline phosphatase; BMI, body mass index; ECOG PS, Eastern Cooperative Oncology Group performance status; LDH, lactate dehydrogenase; LMR, lymphocyte to monocyte ratio; SLD, sum of longest tumour diameters; NLR, neutrophil to lymphocyte ratio; WBC, white blood cells.

Table S4 Model coefficients, their average and weight of points (0 to 5) for significant prognostic factors determined from the multivariable cox proportional hazards regression of the association between clinicopathologic factors and OS/PFS.

Variable	Coefficients - OS model	Coefficients - PFS model	Scaled coefficient average
Age			
27-65	.	.	.
65-86	NA	NA	NA
Sex			
F	.	.	.
M	NA	0.076	1
Race			
Asian	.	.	.
Other	NA	NA	NA
Smoking history			
Never smoked	.	.	.
Ex or current smoker	0.076	0.156	2
Time since diagnosis			
>12 months	.	.	.
<12 months	0.180	0.191	4
Any previous treatment			
No	.	.	.
Yes	NA	NA	NA
ECOG PS			
0	.	.	.
1+	0.050	0.040	1
EGFR mutation type			
DEL19	.	.	.
L858R	0.011	NA	0
Other	NA	NA	NA
T790M	NA	0.484	5
Stage at screening			
IIIB	.	.	.
IV	0.039	NA	0
No. of organs with metastases	0.199	0.116	3
BMI			
>18.5	.	.	.
<18.5	NA	NA	NA
ALP >ULN			
N	.	.	.
Y	NA	NA	NA

Continued

Continued

Variable	Coefficients - OS model	Coefficients - PFS model	Scaled coefficient average
LDH >ULN			
N	.	.	.
Y	0.066	0.145	2
Total protein <LLN			
N	.	.	.
Y	NA	NA	NA
Platelets >ULN			
N	.	.	.
Y	0.047	NA	0
Haemoglobin <LLN			
N	.	.	.
Y	0.050	0.070	1
WBC >ULN			
N	.	.	.
Y	0.322	0.199	5
NLR >4			
N	.	.	.
Y	NA	NA	NA
LMR <3			
N	.	.	.
Y	0.062	0.021	1

<LLN, below the lower limit of normal; >ULN, above the upper limit of normal; ALP, alkaline phosphatase; BMI, body mass index; ECOG PS, Eastern Cooperative Oncology Group performance status; LDH, lactate dehydrogenase; LMR, lymphocyte to monocyte ratio; SLD, sum of longest tumour diameters; NLR, neutrophil to lymphocyte ratio; WBC, white blood cells.




Figure S1 (A) OS and (B) PFS by prognostic group for patients treated with first-line afatinib in Lux-Lung 3 and 6 (development data).




Figure S2 (A) OS and (B) PFS by prognostic group for patients treated with afatinib in Lux-Lung 1.




Figure S3 (A) OS and (B) PFS by prognostic group for patients treated with afatinib in Lux-Lung 2.




Figure S4 Comparison of OS and PFS in patient treated with afatinib versus chemotherapy, according to prognostic group.